Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB204 in moderate to severe acne vulgaris
NCT02242760Phase 2Completed
- Sponsor
- Novan
- Start
- Nov 2014
- Primary completion
- Jun 2015
- Modality
- Polymer-based Nanoparticles, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of berdazimer in acne vulgaris (5 arms), sponsored by Novan. Primary endpoints: Absolute Change in Inflammatory Lesion Counts at 12 weeks, Absolute Change in Non-inflammatory Lesion Counts at 12 weeks and 1 more. Started Nov 2014; status: completed.
02
Drugs
berdazimer
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02242760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242760.